2025
An integrative analysis of circulating and tumor microenvironment (TME) determinants of patient response in the Checkmate 9ER (CM 9ER) trial of nivolumab and cabozantinib (NIVO+CABO) in advanced renal cell carcinoma (aRCC).
Braun D, Vemula S, Cook D, Verma A, Carrigan P, Kelly K, Choueiri T, Gupta S. An integrative analysis of circulating and tumor microenvironment (TME) determinants of patient response in the Checkmate 9ER (CM 9ER) trial of nivolumab and cabozantinib (NIVO+CABO) in advanced renal cell carcinoma (aRCC). Journal Of Clinical Oncology 2025, 43: 4511-4511. DOI: 10.1200/jco.2025.43.16_suppl.4511.Peer-Reviewed Original ResearchAdvanced renal cell carcinomaPD-L1 stainingObjective response rateTumor microenvironmentLogistic regression modelsPD-L1Patient responseIncreased objective response rateTumoral PD-L1 stainingCirculating factorsDeterminants of therapeutic responseTumor response to therapyCirculating immune cell populationsTrials of nivolumabResponse to therapyImmune cell populationsRenal cell carcinomaCancer cell numberPlasma cell numbersCell numberActivation of stromal cellsAssociated with responseExtracellular matrixProgression-FreeRegression models
2016
Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View
Kronbichler A, Saleem M, Meijers B, Shin J. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View. Journal Of Immunology Research 2016, 2016: 2068691. PMID: 27504461, PMCID: PMC4967695, DOI: 10.1155/2016/2068691.Peer-Reviewed Original ResearchConceptsSoluble urokinase-type plasminogen activator receptorFocal segmental glomerulosclerosisPathogenesis of focal segmental glomerulosclerosisSoluble urokinase-type plasminogen activator receptor levelsSegmental glomerulosclerosisProgression to end-stage renal failureEnd-stage renal failureUrokinase-type plasminogen activator receptorSerum suPAR levelsSoluble urokinase receptorIn Vivo Mouse ModelPlasminogen activator receptorImmunologically active cellsPrimary glomerular disordersSuPAR levelsRenal transplantationRenal failureSecondary causesMouse modelCirculating factorsGlomerular diseaseGlomerular disordersActivator receptorUrokinase receptorHuman studiesPathogenesis of minimal change nephrotic syndrome: an immunological concept
Kim S, Park J, Han K, Kronbichler A, Saleem M, Oh J, Lim B, Shin J. Pathogenesis of minimal change nephrotic syndrome: an immunological concept. Clinical And Experimental Pediatrics 2016, 59: 205-211. PMID: 27279884, PMCID: PMC4897155, DOI: 10.3345/kjp.2016.59.5.205.Peer-Reviewed Original ResearchMinimal change nephrotic syndromePathogenesis of MCNSIdiopathic nephrotic syndromeT cellsNephrotic syndromeB cellsAdult minimal change nephrotic syndromeInvolvement of T cellsInduction of CD80T-cell disordersRegulatory T cellsB cell biologyImpaired autoregulatory functionTreatment of childhoodGlomerular filtration barrierTherapeutic responseMassive proteinuriaCirculating factorsSyndromeImmunological conceptsPathogenesisFiltration barrierIncreased levelsAutoregulatory functionChildren
2008
N-acylphosphatidylethanolamine, a Gut- Derived Circulating Factor Induced by Fat Ingestion, Inhibits Food Intake
Gillum MP, Zhang D, Zhang XM, Erion DM, Jamison RA, Choi C, Dong J, Shanabrough M, Duenas HR, Frederick DW, Hsiao JJ, Horvath TL, Lo CM, Tso P, Cline GW, Shulman GI. N-acylphosphatidylethanolamine, a Gut- Derived Circulating Factor Induced by Fat Ingestion, Inhibits Food Intake. Cell 2008, 135: 813-824. PMID: 19041747, PMCID: PMC2643061, DOI: 10.1016/j.cell.2008.10.043.Peer-Reviewed Original ResearchConceptsFood intakeInhibits food intakeTreatment of obesityNovel therapeutic targetCentral nervous systemUnknown physiological significanceFat ingestionCirculating factorsN-acylphosphatidylethanolaminePlasma lipidsIntracerebroventricular infusionPhysiologic dosesSystemic administrationTherapeutic targetBody weightNervous systemIngested fatSmall intestineIntakeTaste aversionInfusionPhysiological significanceNanomolar amountsObesityHypothalamus
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply